Introduction

Platelets are small anuclear cells shed from the megakaryocyte, at a rate of ~10^{11}/day [1], maintaining a blood concentration of 100-450 x 10^9/L in healthy adults. As the second most abundant circulating cells, they are becoming increasingly recognized for their versatility and cross-talks in cancer, development, immunology among others [2,3]. Classically, they are essential for hemostasis; as the first cellular responders to vascular injury, they sense and aggregate at sites of exposed subendothelial matrix proteins forming the initial cellular plug and scaffold for the coagulation cascade, leading to stabilized hemostatic plug formation and ultimately arrest of bleeding [4-6]. Thus, immune disorders such as autoimmune thrombocytopenia (ITP) that target one’s own platelets or megakaryocytes can lead to devastating bleeding and even death. ITP has an incidence of 3.3/100,000 and a prevalence of 9.5/100,000 worldwide and often occurs with insidious onset in adults [7,8]. Characterized by chronic thrombocytopenia, these patients experience bleeding symptoms and are at constant risk for fatal hemorrhage [9]. They frequently suffer co-morbidities such as fatigue, increased risk of infection, hematological malignances and an overall decrease in health-related quality of life.
The Dichotomy of Anti-GPIb and Anti-GPIIβIIIa Mediated ITP and Challenges to First-line Therapies

GPIbα and GPIIβIIIa are distinct antigenic targets

Since Harrington's seminal experiment in the 1950's, it is now widely accepted that autoantibodies (immunoglobulin (IgG)) is the predominant mechanism mediating platelet/megakaryocyte destruction in ITP [16]. Although, cytotoxic T-cells and complement may also play a role [17-19]. Autoantibodies are generated from aberrant self-antigen presentation, which results in T-cell dependent B-cell isotype class switch and IgG production (predominantly IgG1) in the spleen [20]. The primary antibody targets are the two most abundantly expressed platelet surface receptors GPIb-IX complex and integrin GPIIβIIIa (αIββ3) (~25,000 copies and ~80,000 copies/platelet, respectively) [21]. While both these receptors are essential in hemostasis, they are distinct in function and structure.

GPIbα is the largest subunit of the GPIb-IX complex and possesses all the known ligand binding sites. It is comprised of a N-terminus leucine rich repeat followed by a long flexible “stalk” macroglycopeptide region (which constitutes an impressive ~60% of total platelet sialic-acid content) and a juxtamembrane mechanosensory domain [22,23]. Possessing mechanosensory properties, it is one of the first receptors engaged in platelet activation, where stable binding to exposed A1 domain of immobilized von Willabrand (VWF) factor under arterial high shear stress initiates inside-out signaling and stable platelet adhesion [24,25]. This leads to platelet activation including platelet granule release and the critical GPIIβIIIa integrin activation [26]. In addition to binding VWF, other well-known ligands of GPIbα include thrombin, kininogen, P-selectin, thrombospondin and others [24]. GPIb-IX complex is exclusively expressed on platelet and megakaryocytes, and has been functionally implicated in a variety of processes beyond hemostasis and thrombosis including immune regulation (e.g. sepsis, infections), cancer, stroke, angiogenesis and megakaryopoiesis [24]. And recently we have reported the requirement of GPIbα for platelet mediated hepatic TPO generation [27]. It is estimated that of those ITP patients with detectable autoantibodies, ~20-40% are positive for anti-GPIbα [21]. Given the cross functional roles of GPIbα, we are only beginning to elucidate the effects GPIbα antibody targeting.

GPIIβIIIa is a classical integrin, expressed as a heterodimer comprised of non-covalently associated αIIb and β3 subunits [28]. As with other integrins, GPIIβIIIa must undergo a divalent cation dependent conformation change from low-affinity (bent) to a high-affinity active state (extended) for stable adhesion to its ligand(s) [4,29]. Activation of GPIIβIIIa directly follows synergistic inside-out signaling mediated by other platelet receptors such as GPIbα, GPVI, αIIβ1 etc. Receptor occupancy of GPIIβIIIa with fibrinogen or other ligands leads to platelet cross-linking and aggregation as well as GPIIβIIIa outside-in signaling and a second wave of platelet activation [30-33]. The canonical ligand of GPIIβIIIa usually consists of a simple RGD peptide sequence and binds at the interface between the β-propeller subunit of αIIb and the A like-domain of β3. However, GPIIβIIIa does not exclusively bind RGD-containing ligands, as in the case of fibrinogen (C-terminus KQAGDV sequence) or our recently identified novel anti-thrombotic Apolipoprotein A-IV [34,35]. While the principle ligands such as fibrinogen or VWF are not indispensable for platelet aggregation, GPIIβIIIa is essential, and thus critically important for hemostasis [31,36]. Interestingly, there exists quantitatively, a hemostatic threshold for platelet GPIIβIIIa, where ~50% of normal GPIIβIIIa expression is sufficient to maintain hemostasis (i.e. heterozygous Bernard-Soulier patients do not exhibit significant bleeding) [37]. Most autoantibodies in ITP are directed against GPIIβIIIa (~60%) and are predominantly targeted against αIIb subunit. However, it was found binding of these autoantibodies is usually divergent cation dependent and requires β3 subunit as an intact αIIbβ3 structure [38]. Putatively, autoantibodies that block the ligand binding site, or ‘lock’ the conformational state of GPIIβIIIa could inhibit platelet function in ITP [14] (Figure 1). Conversely, antibodies may also reveal cryptic ligand induced binding sites, causing abnormal GPIIβIIIa activation[39,40]. ITP sera that are activating or inhibitory have been reported, furthermore, there is evidence that platelet function in ITP patients may be a better predictor of bleeding tendency than platelet number [41].

Given the unique roles of these respective platelet receptors, it is conceivable that antibody binding could...
manifest discrepant outcomes in both bleeding tendency and response to treatment. We and others have demonstrated that in contrast to anti-GPIIbIIIa, anti-GPIbα mediated ITP can be Fc-independent whereby neither the Fc-region of antibody nor the corresponding FcγR are required for antibody mediated clearance [42,43]. This also led to IVIG resistant ITP [42,44]. Our initial observations in mouse models have been recapitulated in subsequent human clinical studies; it has since been reported that presence of anti-GPIbα antibodies in ITP is sufficient to render the patients more refractory to common first-line therapies including steroids, IVIG, and others including Rituximab [44-48].

**Anti-GPIbα antibodies mediate platelet activation desialylation in a positive feed-back loop**

In 2015, we were the first to elucidate one mechanism by which anti-GPIbα antibodies mediate Fc-independent platelet destruction. We found anti-GPIbα antibodies targeting the N-terminus of GPIbα cause receptor clustering, downstream signaling, leading to platelet activation, granule neuraminidase surface translocation and enzymatic removal of terminal surface sialic acids (desialylation) (Figure 1). This ultimately leads to platelet clearance via non-Fc receptors, of which the Ashwell-Morell Receptor (AMR) is a contributor [49]. We also demonstrated that antibody mediated platelet activation and desialylation exist in a positive feed-back loop whereby increased platelet desialylation potentiates further platelet activation, through enhanced facilitation of GPIbα signaling [49]. We also observed anti-GPIIbIIIa antibodies could induce human platelet activation, predominantly through immune complex binding and activation of human platelet FcγRIIa (Figure 1). However, anti-GPIbα antibodies were more prone to mediate platelet activation/desialylation and Fc-independent

![Figure 1](image-url)

**Figure 1:** Antibody specificity leads to differential platelet responses and clearance mechanisms. Anti-GPIbα and anti-GPIIbIIIa antibodies that target the N-terminus of the receptors have disparate effects. Anti-GPIbα antibodies will cause platelet activation (inside-out signaling) and desialylation which will lead to predominant Fc-independent platelet clearance in the liver (Red). Anti-GPIIbIIIa antibodies may block fibrinogen binding or inhibit conformational change (inhibitory antibodies) or they may cause exposure of ligand binding site and GPIIbIIIa activation (Purple). Anti-GPIIbIIIa antibodies could also cause platelet activation through immune complex binding with FcγRIIa (Black), which could also result in “semi-” Fc-independent platelet clearance in the liver. Other uncharacterized antibody binding sites which could modulate platelet function and clearance include the macroglycopeptide and mechanosensory region on GPIbα, the PSI-domain on β3 subunit, the β-propeller domain on αIIb subunit (green).
clearance as it likely through N-terminus F(ab’)2 binding. An FcyRIIA-GPIbα complex mediated activation via N-terminus binding antibodies may be less feasible than GPIIbIIIa, due to the long length of GPIbα (~40 nm compared with ~20 nm, Figure 1) [50]. As bivalency of antibody is required (anti-GPIbα Fab does not induce Fc-independent platelet clearance), it is postulated that antibody crosslinking of GPIbα may mimic the signaling triggered by receptor binding of VWF multimers [49,51]. However, antibody binding site/epitope appears to be critical in anti-GPIbα antibody mediated platelet activation, as antibodies targeting non-N-terminus regions such as the mechanosensory region, which also causes receptor clustering, nevertheless fails to induce platelet activation and Fc-independent platelet clearance [52]. Recently it was suggested, shear is an important factor in this process, thus high affinity antibodies that can exert a pulling force under shear causing an unfolding of the mechanosensor domain, are more adept at inducing GPIbα activation [23]. However, the exact binding epitopes that confer activating properties to anti-GPIbα antibodies remains to be further studied.

The presence of platelet activating antibodies such as anti-GPIbα may predispose a more severe disease. Low antibody titers causing consumptive platelet microaggregate formation leads to an amplified and disproportionate thrombocytopenia. In addition, binding of anti-GPIbα at the N-terminus may block endogenous ligand binding, rendering the remaining platelets hemostatically impotent and exacerbating bleeding tendency (Figure 1). This culminates in a particularly severe and likely refractory disease, as we observed in an unfortunate fatal case of anti-GPIbα mediated ITP [53]. We also recently uncovered the requirement for GPIbα N-terminus for platelet mediated hepatic TPO generation, which could be blocked in the presence of anti-GPIbα antibodies [27]. This in combination with previous reports indicating the essential role of GPIbα for normal late stage megakaryopoiesis (thrombopoiesis) and proplatelet formation, suggests platelet GPIbα N-terminus is a significant contributor in platelet production which may be significantly impacted in presence of anti-GPIbα antibodies [54,55].

Anti-GPIbα antibodies mediated platelet desialylation leads to non-classical Fc-independent clearance in the liver

A critical downstream consequence of anti-GPIbα antibody mediated platelet activation is platelet desialylation [23,49]. Removal of terminal sialic acids, particularly on GPIbα itself, primes platelets for rapid removal via non-FcγR pathways in the liver, rather than expected splenic Fc-FcγR mediated clearance. Attenuation of neuraminidase enzyme activity with pharmacological inhibitors such as Oseltamivir (Tamiflu®) has been demonstrated to decrease platelet desialylation and increase platelet counts in our murine models and human ITP patients [48,56-58]. Reciprocally, we and others have identified the AMR as one of the non-Fc receptors that contributes to desialylated platelet clearance [49,59]. However, contributions of other lectin receptors such as Mac-1 (αMβ2) on Kupffer cells are not well investigated. Kupffer cells are strategically positioned within the liver vessel lumen (lining the sinusoids) which facilitates interaction with circulating platelets [60]. Kupffer cell-platelet interactions have been reported to contribute to a variety of biological processes including liver injury, infection, and liver regeneration [61]. It is likely that they also significantly contribute to desialylated/apoptotic platelet clearance. There are emerging reports identifying αMβ2 cognate ligands on platelet surface including O-linked deglycosylated residues, but it’s role in ITP is not known [62]. Furthermore, the immunological consequences of platelet clearance within immunological disparate organs (spleen versus liver) has not been adequately studied, although our preliminary data show an immunosuppressive response associated with liver platelet clearance.

Platelet Desialylation: A New Diagnostic Biomarker and Therapeutic Target in ITP

Current first line therapies in ITP include corticosteroids, IVIG, and/or anti-D. Although a good proportion of patients exhibit an initial response (up to 80%), durable response is difficult to achieve; long-term follow up frequently reveal significant drop in responders particularly following tapering or withdrawal of the drug (down to ~40%) [13]. In addition, cost, bioavailability (e.g. IVIG, anti-D) and drug related toxicities are of real concern. Paradoxically, risks associated with taking common treatments such as corticosteroids and IVIG sometimes outweigh the risk associated with ITP itself [11]. For those that fail first line therapies, second-line and third-line therapies including rituximab (B-cell depletion with an anti-CD20 monoclonal antibody), TPO receptor agonists (TPO-RA) (eltrombopag, avatrombopag, romiplostim), and less commonly fostamatinib (an FcyR Syk inhibitor) and other immunosuppressive drugs (mycophenolate, azathioprine, and cyclosporine) are either given alone or in combination. As there are no benchmark guidelines, these are administered on a ‘trial and error’ basis [63]. Splenectomy, a permanent surgical procedure with lifelong safety concerns, is now on the decline due to the conflicting data regarding its therapeutic superiority compared to pharmacological
interventions such as rituximab or TPO-RA [13]. As with other ITP treatments prognostic markers are lacking, although it has been observed hepatic sequestration of radioisotope-labeled platelets is correlated with decreased response [64].

As most of the aforementioned ITP therapies target Fc-dependent platelet clearance mechanisms (e.g. IVIG, anti-D, rituximab, fostamatinib, splenectomy), it logically follows antibodies causing non-splenic Fc-independent platelet clearance will be less responsive. Since we have identified desialylation as a marker in both antibody mediated platelet activation and Fc-independent clearance, clinical studies have been initiated to assess prognostic potential of desialylation as a biomarker for refractory ITP and the therapeutic potential of neuraminidase inhibitor Oseltamivir (Tamiflu®) [48]. Recently, our clinical study of 61 ITP patients demonstrated higher platelet desialylation in patients was correlated with non-response to corticosteroids and IVIG first-line treatments [65]. The relatively simple protocol of detecting binding of Ricinus Agglutinin I (RCA-1) to desialylated platelet residues via flow cytometry suggests a feasible prognostic assay for assessment of potentially refractory patients, although large scale clinical study is required to confirm this finding. Lessons learned from these emerging clinical studies suggest 1) increased refractoriness in ITP may be associated with platelet desialylation [48,65-67] and 2) platelet desialylation is not exclusively linked with anti-GPIIbα antibodies, although presence of anti-GPIIbα antibodies may increase propensity for platelet desialylation, other mechanisms such as CD8+ cytotoxic T-cells may also contribute [48,65,68]. Additionally, anti-GPIIbIIIa antibodies may also mediate platelet desialylation through human platelet FcyRIIa as we previously reported, which was also observed in human ITP patients [65,69]. Although in the latter study, there appeared to be a greater propensity for hepatic clearance in the presence of anti-GPIIbα antibodies, despite not reaching statistical significance.

Tamiflu®, an FDA approved neuraminidase inhibitor typically used to treat influenza was previously shown to also effective on platelet sialidases and increased platelet sialylation [58]. Since we identified platelet desialylation as a Fc-independent clearance pathway in ITP, several case studies as well as ITP patient cohorts have demonstrated therapeutic benefit either alone or in combination with other ITP treatments, particularly in the refractory patient subset [48,56,57,70]. Although the data show platelet desialylation levels are decreased in ITP patients following successful response to sialidase inhibitors, other pathways which contributes to therapeutic effect including prolonging platelet lifespan through decreasing aged-related platelet desialylation or other off-target desialylation inhibition including that of pathogenic lymphocytes cannot be excluded.

**Future Perspectives**

It is becoming increasingly clear that ITP can no longer be considered a homogeneous disease. Indeed, patients often experience great variability in bleeding tendency independent of platelet count, as well as inconsistent response to therapeutics. Our recent findings highlighting differential pathways of antibody mediated effects on platelets and platelet clearance represent one facet of the heterogeneity that may exist within the disease pathology. While these findings were discussed in the context of ITP, they may also be applicable to other immune-mediated thrombocytopenic disorders in which anti-platelet antibodies are present, such as alloimmune thrombocytopenias (e.g. fetal neonatal alloimmune thrombocytopenia, post-transfusion purpura etc.) or secondary ITP. Although great strides have been made to elucidate pathobiological differences between refractory or severe ITP subset and responders, our understanding of its mechanisms are still in its infancy. Larger scale clinical trials are needed to evaluate the utility of reliable prognostic biomarkers (e.g. anti-GPIIbα antibodies and desialylation) which will optimize personalized treatment, as well as alleviate healthcare cost burden.

**Financial Support and Sponsorship**

This work was supported in part by Canadian Institutes of Health Research (MOP 97918, MOP 119540, MOP 119551) and Canadian Blood Services- Canadian Institutes of Health Research partnership fund (CIHR-BUC201403-HN-326400). J.L. is a recipient of a Ph.D. Graduate Student Fellowship from Canadian Blood Services. J.A.S. is a recipient of the Canadian Institutes of Health Research Canadian Graduate Student – Master Award and the Laboratory Medicine and Pathobiology Departmental Fellowship from the University of Toronto.

**Conflicts of Interest**

No conflicts of interest to disclose.

**References**


33. Reheman A, Tasneem S, Ni H, Hayward CP. Mice with deleted multimerin 1 and α-syneulin genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1. Thrombosis research. 2010 May 1;125(5):e177-83.


41. Frelinger III AL, Grace RF, Gerrits AJ, Carmichael SL, Forde EE, Michelson AD. Platelet function in ITP, independent of platelet count, is consistent over time and is associated with both current and subsequent bleeding severity. Thrombosis and haemostasis. 2018 Jan;118(01):143-51.


